Biodexa Pharmaceuticals PLC ADR美股招股说明书(2025-01-08版)

BIODEXA PHARMACEUTICALS PLC 115,102,400 Ordinary Shares Representing 287,756 American Depositary Shares This prospectus supplement No. 18 (the “Prospectus Supplement”) amends and supplements our prospectuscontained in our Post-Effective Amendment No. 1 to Registration Statement on Form F-1, effective as of May 2,2024 (the “Prospectus”), related to the resale by the selling shareholders identified in the Prospectus of up to anaggregate of 115,102,400 of our ordinary shares, nominal value £0.001 per share, represented by 287,756 AmericanDepositary Shares (the “Depositary Shares”). This Prospectus Supplement is being filed in order to incorporate into and include in the Prospectus theinformation contained in our attached Form 6-Ks, filed with the Securities and Exchange Commission on December4, 2024 and December 27, 2024, respectively. This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified by referenceto the Prospectus except to the extent that the information in this Prospectus Supplement supersedes the informationcontained therein. Our Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.” The lastreported closing price of Depositary Shares on the NASDAQ Capital Market on January 6, 2025 was $4.45. Investing in our securities involves risks. See “Risk Factors” beginning on page 11 of the Prospectusand in the documents incorporated by reference in the Prospectus for a discussion of the factors you shouldcarefully consider before deciding to purchase these securities. Neither the Securities and Exchange Commission nor any state securities commission has approvedor disapproved of these securities or determined if this prospectus is truthful or complete. Any representationto the contrary is a criminal offense. The date of this Prospectus Supplement is January 7, 2025. REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16 OF THESECURITIES EXCHANGE ACT OF 1934 For the month of December 2024Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point,Caspian WayCardiff, CF10 4DQ, United Kingdom(Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40- F: Form 20-FxForm 40-Fo Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1):o Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7):o The information included in this Report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated byreference into the registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333-267932) of the Company (including any prospectuses forming a part of such registration statements) and to be apart thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents orreports subsequently filed or furnished. SUBMITTED HEREWITH Attached to the Registrant’s Form 6-K filing for the month of December 2024, and incorporated by reference herein,is: 99.1Press Release dated November 22, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to besigned on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC By:/s/ Stephen StampStephen StampChief Executive Officer and Chief Financial Officer November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting BiodexaPharmaceuticals PLC(“Biodexa”or the“Company”)(NASDAQ:BDRX),a clinical stagebiopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmetmedical needs announces, announces that at its General Meeting held earlier today, both resolutions put to theCompany’s shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting and General MeetingcanbefoundintheNoticeoftheGeneralMeetingontheCompany'swebsiteat:https://biodexapharma.com/investors/corporate-governance/#agms. The effect of the resolutions is solely to reduce the nominal, or par, value per ordinary share. There is no change tothe number of ordinary shares outstanding. About Biodexa Pharmaceuticals PLCBiodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. TheCompany’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis andNon-Muscle Invasive Blader Cancer; tolimidone, under development for the treatment of type 1 diabetes; andMTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a p